The challenge of finding a cure for HIV infection.
Although combination therapy for HIV infection represents a triumph for modern medicine, chronic suppressive therapy is required to contain persistent infection in reservoirs such as latently infected CD4+ lymphocytes and cells of the macrophage-monocyte lineage. Despite its success, chronic suppressive therapy is limited by its cost, the requirement of lifelong adherence, and the unknown effects of long-term treatment. This review discusses our current understanding of suppressive antiretroviral therapy, the latent viral reservoir, and the needs for and challenges of attacking this reservoir to achieve a cure.
Richman
Douglas D
DD
San Diego VA Healthcare System and University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0679, USA. drichman@ucsd.edu
Margolis
David M
DM
Delaney
Martin
M
Greene
Warner C
WC
Hazuda
Daria
D
Pomerantz
Roger J
RJ
D016915:AIDS Vaccines; D000818:Animals; D019380:Anti-HIV Agents / Q000191:economics / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000191:economics; D015496:CD4-Positive T-Lymphocytes / Q000821:virology; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D006678:HIV / Q000187:drug effects* / Q000502:physiology; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D014766:Viremia / Q000188:drug therapy; D017735:Virus Latency / Q000187:drug effects*; D014779:Virus Replication / Q000187:drug effects
D016915:AIDS Vaccines; D019380:Anti-HIV Agents